Bcl2L10 also represents apredictive factor for resistance to azacitidine in myelodysplastic syndromes andacute myeloid leukemia patients [25], and for response to neoadjuvant chemoradiotherapy in locallyadvanced rectal cancer [9] orto death-inducing agents in breast cancer [12]. The gene discussed is BCL2L10; the disease is breast cancer.